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Pntifibrotic Effects of Antioxidant
-Acetylcysteine in a Mouse Model
f Human Hypertrophic Cardiomyopathy Mutation
li J. Marian, MD, FACC, Vinitha Senthil, PHD, Suet N. Chen, MS, Raffaella Lombardi, MD
ouston, Texas
OBJECTIVES The objective was to determine the effects of antioxidant N-acetylcysteine (NAC) on reversal
and attenuation of established interstitial fibrosis in the cardiac troponin T (cTnT) mouse
model of human hypertrophic cardiomyopathy (HCM) mutation.
BACKGROUND Interstitial fibrosis is a characteristic pathological feature of HCM and a risk factor for sudden
cardiac death. The cTnT-Q92 transgenic mice, generated by cardiac-restricted expression of
human HCM mutation, show a two- to four-fold increase in interstitial fibrosis.
METHODS We randomized the cTnT-Q92 mice to treatment with a placebo or NAC (250, 500, or
1,000 mg/kg/day) and included non-transgenic mice as controls (N 5 to 13 per group). We
performed echocardiography before and 24 weeks after therapy, followed by histologic and
molecular characterization.
RESULTS There were no significant differences in the baseline characteristics of the groups. Treatment with
NAC reduced myocardial concentrations of malondialdehyde and 4-hydroxy-2(E)-nonenal,
markers of oxidative stress, by 40%. Collagen volume fractions comprised 1.94  0.76% of the
myocardium in non-transgenic, 6.2  1.65% in the placebo, and 1.56  0.98% in the NAC
(1,000 mg/kg/day) groups (p 0.001). Expression levels of Col1a1 and Col1a2 were also reduced
significantly, as were levels of phosphorylated but not total p44/42, p38, and c-Jun NH2-terminal
kinase. Levels of oxidized mitochondrial and nuclear DNA were not significantly different.
CONCLUSIONS Treatment with NAC reduced myocardial oxidative stress, stress-responsive signaling kinases,
and fibrosis in a mouse model of HCM. The potential beneficial effects of NAC in reversal
of cardiac phenotype in human HCM, the most common cause of sudden cardiac death in
the young, merits investigation. (J Am Coll Cardiol 2006;47:827–34) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.041American College of Cardiology Foundation
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Typertrophic cardiomyopathy (HCM) is a relatively com-
on disease characterized clinically by diastolic heart failure
nd sudden cardiac death (SCD) and pathologically by myo-
yte hypertrophy, disarray, and interstitial fibrosis (1,2).
ypertrophic cardiomyopathy is the most common cause of
CD in the young and a major cause of morbidity in elderly
3). Several clinical and pathological phenotypes, including
he extent of interstitial fibrosis, have been associated with
he risk of SCD and diastolic heart failure in HCM (4–6).
The genetic basis of HCM has been all but elucidated,
nd several hundred mutations in over a dozen sarcomeric
roteins have been identified (1). In addition, mutations in
everal non-sarcomeric genes have been associated with
ardiac hypertrophy. The latter phenotype is considered a
henocopy and not true HCM (1). Genotype-phenotype
orrelation studies show a considerable overlap in the pheno-
ypic expression of HCM, and no phenotype is considered
nique to a specific gene or mutation (7). Nevertheless, despite
he presence of significant variability, the causal mutations
mpart considerable effects on the phenotypic expression of
CM. Accordingly, mutations in cardiac troponin T (cTnT),
major gene for HCM (1,8), are generally associated with
From the Section of Cardiology, Department of Medicine, Baylor College of
edicine, Houston, Texas. Supported by grants from the National Heart, Lung, and
lood Institute, Specialized Centers of Research P50-HL54313, RO1 HL68884, and
rants from Greater Houston Community Foundation (TexGen) and The Methodist
eBakey Heart Center.C
Manuscript received July 15, 2005; revised manuscript received September 27,
005, accepted October 3, 2005.elatively mild hypertrophy but severe myocyte disarray and
nterstitial fibrosis (8–11). The observed phenotype is recapit-
lated in the transgenic mouse models expressing mutant
TnT proteins, which show myocyte disarray and interstitial
brosis but no discernible cardiac hypertrophy (12–15).
The pathogenesis of cardiac phenotype in HCM is largely
nknown. We and others have proposed that the initial
henotypes imparted by the mutant sarcomeric proteins, al-
hough diverse, are functional (16). Accordingly, morphologic
nd histologic phenotypes are secondary phenotypes and hence
ould be reversed, attenuated, or prevented through interven-
ions aimed at blocking the intermediary molecular phenotypes
17,18). Concerning the pathogenesis of interstitial fibrosis,
he balance between oxidants and antioxidants is considered
mportant for maintaining normal collagen homeostasis
19,20). Treatment with antioxidants, such as N-acetylcysteine
NAC), has been shown to attenuate interstitial fibrosis in
everal pathological states but not in the myocardium
19,20). Thus, we performed a randomized study to deter-
ine whether treatment with NAC could reverse or atten-
ate evolving interstitial fibrosis in the CTnT-Q92 trans-
enic mouse model of HCM, known to show a two- to
our-fold increase in interstitial fibrosis (12,15).
ATERIALS AND METHODS
he cTnT-Q92 transgenic mice. The Animal Subjects
ommittee of Baylor College of Medicine approved the experi-
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N-Acetylcysteine and Fibrosis in HCM February 21, 2006:827–34ents. The cTnT-Q92 transgenic mouse model has been pub-
ished (12,15,17,21). In brief, cardiac-restricted expression of
TnT-Q92 leads to myocyte disarray, encompassing 10% to 30%
f the myocardium, a two- to four-fold increase in interstitial
ollagen content, no cardiac hypertrophy, and increased Ca2
ensitivity of isolated cardiac myofilaments (12,15,17,21).
andomized placebo-controlled therapy. We random-
zed adult age- and gender-matched cTnT-Q92 mice to
reatment with a placebo or NAC administered at 1,000
g/kg/day (N  13 per group). Age- and gender-matched
on-transgenic mice (NTG) were included as controls (n 
3). To determine an effective dose range on interstitial
brosis, two additional smaller groups of cTnT-Q92 were
reated with 250 and 500 mg/kg/day of NAC (N  5 per
roup). All mice underwent two-dimensional and Doppler
chocardiography before randomization and on completion
f the six-month treatment. The mean daily water con-
umption per mouse was determined, and then aliquots of 7,
.5, and 1.75 g NAC were dissolved in 800 ml water (pH
as adjusted to 6.7) to deliver approximately 250, 500, and
,000 mg/kg/day NAC to each mouse. The placebo group
as given water alone. The duration of therapy was 24
eeks. After follow-up echocardiography, mice were eutha-
ized for morphometric and molecular phenotyping.
mode, two-dimensional, and Doppler echocardi-
graphy. Transthoracic and Doppler echocardiography
ere performed before and after completion of NAC therapy
sing an HP 5500 Sonos echocardiography unit equipped
ith a 15-MHz linear transducer, as published (15).
yocardial lipid peroxide levels. Myocardial levels of
alondialdehyde (MDA) and 4-hydroxyalkenals (HAE),
he end products derived from peroxidation of polyunsatu-
ated fatty acids and related esters, were measured using a
ommercially available kit per instructions of the manufac-
urer (Calbiochem Inc., San Diego, California). The assay is
ased on the spectrophotometric measurement of a chro-
ophore at 586 nm, generated by condensation of either
DA or 4-HAE, with two molecules of N-methyl-2-
henylindole, as the chromogenic reagent. The reactions
ere performed in triplicate and in eight animals per group.
orphometric analyses. All morphometric analyses were
erformed by an investigator who had no knowledge of the
roup assignment and in a random order of groups. Colla-
Abbreviations and Acronyms
cTnT  cardiac troponin T
CVF  collagen volume fraction
HCM  hypertrophic cardiomyopathy
JNK  c-Jun NH2-terminal kinase
MMP  matrix metalloproteinase
mtDNA  mitochondrial deoxyribonucleic acid
NAC  N-acetylcysteine
RT-PCR  reverse transcriptase-polymerase chain reaction
SCD  sudden cardiac deathen volume fraction (CVF) was determined by quantitative tutomated planimetry as described previously (15). In brief,
hin ventricular sections, cut parallel to the atrioventricular
roove, were stained with collagen-specific Sirius red F3BA
n 5% saturated picric acid. The percent myocardial area
tained positive for Sirius R was determined in 12 fields per
ach thin section and 10 sections per mouse.
eal-time (RT) polymerase chain reaction (PCR). Ex-
ression levels of selected genes were determined by
uantitative PCR using specific TaqMan probes and oli-
onucleotide primers in a 7900HT Sequence Detection Sys-
em unit (Applied Biosystems, Inc., Foster City, California)
nd were normalized to levels of glyceraldehyde-3-phosphate
ehydrogenase (GAPDH), as described previously (15). In
rief, total cellular RNA was extracted by the guanidinium
sothiocyanate method (TRIzol reagents, Invitrogen Inc.,
arlsbad, California). Expression levels of the mRNAs for
he Col1a1, Col1a2, and Col3A1, which encode procollagen
ol1(1), Col1(2) and Col3(1), respectively, the pre-
ominant cardiac collagens, were quantified by RT-PCR.
xperiments were performed at least three times, and the
ean values were used for comparisons.
solation of mtDNA and detection of oxidized nuclear
NA and mtDNA levels. Nuclear DNA and mtDNA
ere extracted from myocardial tissues as published (22).
he purity of isolated mtDNA was determined by gel
lectrophoresis of mtDNA digested with BamHI. Immuno-
lot blots were performed after incubation of the membranes
ith an anti-7,8-dihydro-8-oxo-guanine antibody (22). The
ntensity of the signal was quantified by densitometry and
ompared among the groups (N  6 per group).
mmunoblotting. Expression levels and activation of se-
ected signaling molecules implicated in mediating response to
xidative stress, including total and phosphorylated p44/42,
38, and c-Jun NH2-terminal kinases (JNK), were detected as
escribed (15). To re-probe, the membranes were stripped by
ncubating in 1% sodium dodecyl sulphate and 100 mM
-mercaptoethanol in Tris buffered saline (TBS) for 30 min at
oom temperature and then washed in TBS at least six times. The
embraneswere probedwith specific antibodies to detect levels of
otal signaling proteins as well as levels of tubulin (monoclonal
ouse antitubulin from Santa Cruz, Santa Cruz, California) or
arcomeric actin as controls for loading conditions. Each set of the
xperiments was repeated three to five times, and expression levels
f the proteins were quantified by spot densitometry.
etection of myocardial matrix metalloproteinase
MMP) activity by zymography. Aliquots (50 mg) of myo-
ardial tissues were homogenized in ice-cold extraction buffer
50 mM Tris-HCl, 75 mM NaCl, and 1 mM phenylmethyl-
ulphonylfluoride, pH 7.5, with 1 ml buffer per 50 mg tissue).
he homogenates were centrifuged at 10,000g at 4°C for 20
in. Protein concentration of the supernatants was determined
y Bradford assay. Protein samples were incubated for 10 min
t room temperature in a double volume of Zymogram Sample
uffer (Bio-Rad Laboratories, Hercules, California) and
oaded onto 10% gel (SDS-PAGE) containing 0.1% gelatin as
he substrate under non-reducing conditions.
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February 21, 2006:827–34 N-Acetylcysteine and Fibrosis in HCMAfter electrophoresis, the gel was incubated in 1 Zymogram
enaturating Buffer (Bio-Rad Laboratories) for 30 min at room
emperature with gentle agitation. The renaturing buffer was
ecanted, and the gel was equilibrated in 1 Zymogram Devel-
ping Buffer (Bio-Rad Laboratories) for 30 min at room temper-
ture with gentle agitation. Gel was then incubated overnight in
resh developing buffer at 37°C. After the reaction, the gel was
tained with 0.5%Coomassie brilliant blue R 250 for 30min, and
estained with methanol:acetic acid:water at a 50:10:40 ratio.
ones of protease activitywere visualized as clear bands against the
ark-blue background and were quantified by quantitative image
nalysis (N  4 per group).
tatistical methods. Homogeneity of the variances was ana-
yzed by Bartlett test. Differences in variables among the non-
able 1. Effects of N-Acetylcysteine on Cardiac Structure and Fu
Non-transgenic
13
ge (months) 9.1  2.2 9
ender (M/F) 7/6
ody weight (g) 34.1  4.3 33
eart rate (beats/min) 415  36 4
ystolic blood pressure (mm Hg) 89  12
iastolic blood pressure (mm Hg) 48  9
chocardiographic parameters
VST (mm)
BL 0.78  0.06 0.
FU 0.81  0.05 0.
WT (mm)
BL 0.80  0.08 0.
FU 0.75  0.05 0.
VEDD (mm)
BL 4.2  0.22 4
FU 4.3  0.37 4
VESD (mm)
BL 3.0  0.27 2
FU 3.1  0.32 2
S (%)
BL 32.0  3.7 44
FU 31.1  5.1 40
VEF (%)
BL 63.7  6.1 79
FU 61.5  7.9 78
cf (cm/s)
BL 5.8  1.1 7
FU 5.4  1.0 6
ortic peak ejection rate (cm/s)
BL 1.04  0.12 1
FU 0.99  0.12 0.
ortic ejection time (ms)
BL 52.5  3.6 62
FU 53.1  6.0 63
/A ratio
BL 2.57  1.2 2.
FU 2.68  1.1 2.
ll pairwise comparisons were performed by Tukey test. The following were compare
etween NTG and cTnT-Q92 (1,000); IVST between BL and FU in the placebo and
nd placebo groups; FS (%) BL and FL values in NAC-1,000 group; LVEF (%)–FU
nd FU values in the placebo group. *p  0.05 as compared with NTG.
BL baseline; cTnT cardiac troponin T; E/A ratiomitral inflow early to late velocities
VEDD  left ventricular end diastolic dimension; NTG  non-transgenic; PWT  posteriransgenic, placebo, and NAC groups were compared by analysis
f variance for variables with equal standard deviation and by the
on-parametric Kurskall-Wallis test for variables with unequal
tandard deviation. Pairwise comparisons were performed by
ukey test. Differences between the baseline and follow-up values
n each group were compared by paired t test for variables with
qual standard deviation and byMann-Whitney test for variables
ith unequal standard deviation.
ESULTS
aseline characteristics of the cTnT-Q92 transgenic
ice. The mean age, male:female ratio, heart rate, blood
ressure, and body weight were not significantly different
mong the groups (Table 1). Cardiac phenotype in the
n in cTnT-Q92 Mice
cTnT-Q92
bo
N-Acetylcysteine (mg/g/d)
250 500 1,000
5 5 13
4.8 8.4  3.6 8.7  3.7 9.5  3.7
3/2 3/2 6/7
2.3 31.9  6.2 33.7  5.4 35.3  3.2
35 436  42 420  37 418  39
17 84  15 99  21 91  16
13 49  11 45  13 43  14
0.04 0.71  0.04 0.74  0.06 0.72  0.04
0.07 0.78  0.03 0.77  0.06 0.76  0.07
0.05 0.75  0.04 0.72  0.03 0.72  0.08
0.08 0.80  0.09 0.76  0.06 0.73  0.05
0.31 3.8  0.33 3.9  0.29 4.3  0.28
0.29 4.1  0.38 3.8  0.35 4.3  0.30
0.44* 2.1  0.33* 2.3  0.40* 2.4  0.31*
0.38* 2.3  0.48* 2.5  0.29* 2.6  0.27*
8.5* 43.5  6.9* 41.1  5.5* 43.3  5.7*
6.5* 43.9  4.8* 42.7  6.2* 39.6  3.5*
8.1* 78.3  5.9* 74.0  7.2* 79.9  6.0*
7.3* 79.0  6.8 76.9  8.4 75.9  4.2*
1.6* 7.4  1.4* 7.1  1.5* 7.2  1.1*
1.7* 7.2  1.8* 6.9  1.7* 6.5  0.7*
0.19 1.0  0.17 0.99  0.12 1.08  0.14
0.15 0.97  0.09 1.03  0.13 1.06  0.12
4.0* 60.1  4.5* 61.1  3.8* 60.3  4.2*
4.5* 62.4  4.3* 60.9  5.3* 57.6  4.3*
0.70 2.17  0.9 2.09  0.8 2.14  0.65
0.34 2.21  1.2 2.22  0.9 2.40  0.84
ruskal-Wallis test because of unequal variances: age between NTG and placebo and
C-1,000 groups; LVEDD between BL and FU values; FS (%) at BL between NTG
en NTG and NAC-1,000; E/A ratio; FU values among the groups; and between BLnctio
Place
13
.3 
7/6
.9 
09 
92 
42 
75 
73 
78 
72 
.0 
.0 
.2 
.4 
.1 
.0 
.9 
.9 
.3 
.8 
.1 
93 
.1 
.8 
01 
40 
d by K
in NA
betwe; FS fractional shortening; FU follow-up; IVST interventricular septal thickness;
or wall thickness; Q  glutamine; Vcf  velocity of circumferential fiber shortening.
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N-Acetylcysteine and Fibrosis in HCM February 21, 2006:827–34TnT-Q92 mice was as published (12,15,17). It was notable
or normal wall thickness, left ventricular end diastolic diam-
ter, aortic outflow maximum velocity, and mitral inflow E
elocity. In contrast, left ventricular end systolic diameter was
maller and three indexes of left ventricular systolic performance,
amely fractional shortening, velocity of circumferential fiber
hortening, and left ventricular ejection fraction, were increased
Table 1). In addition, aortic ejection time was prolonged and
igure 1. Plasma and myocardial levels of lipid peroxides. Myocardial (A) a
re depicted in non-transgenic (NTG) and cardiac troponin T-Q92 (cTnT
p  0.05 for pairwise comparisons.igure 2. Effect of NAC on CVF. Panels in 2A show representative high-magn
ice treated with placebo and cTnT-Q92 mice treated with NAC. (B) Quantiitral inflow E/A velocity was modestly reduced. The CVF was
ncreased by approximately three-fold, andmyocyte disarray com-
rised approximately 20% of the myocardium.
ffects of NAC on cardiac structure and function. All
ice survived the treatment with all three doses of NAC.
reatment with NAC had no significant effect on echocar-
iographic indexes of wall thickness, left ventricular size, or
unction, with the exception of a modest improvement in
sma (B) levels of malondialdehyde (MDA) and 4-hydroxyalkenals (HAE)
2) transgenic mice treated with placebo or with N-acetylcysteine (NAC).nd plaification microscopic fields (400) in non-transgenic (NTG), cTnT-Q92
tative values in the three groups. *p  0.05 for pairwise comparisons.
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February 21, 2006:827–34 N-Acetylcysteine and Fibrosis in HCMitral inflow E/A ratio, which was of borderline statistical
ignificance (Table 1).
ffects of NAC on plasma and myocardial lipid peroxide
evels. Both plasma and myocardial lipid peroxide levels were
educed significantly (40%) in the NAC group (1,000 mg/kg/
ay as compared with the placebo or NTG group (Fig. 1).
ffects of NAC on CVF and myocyte disarray. The CVF,
uantified in 120 high-magnification microscopic fields
400) per mouse, was increased by approximately three-
old in the placebo group as compared with the NTG (Fig.
). The CVF was within the normal range in all three NAC
roups, regardless of the dose. Because all three doses of
AC were effective in reducing CVF to normal levels in the
TnT-Q92 mice, data are primarily presented for the 1,000
g/kg/day group (Fig. 2). Myocyte disarray, determined in
20 high-magnification microscopic fields per mouse, com-
rised 3.1  1.5% of the myocardium in the NTG mice,
2.6 4.1% in the cTnT-Q92 transgenic mice in the placebo
roup (p  0.001 compared with NTG), and 11.0  3.2% in
he NAC group (p  0.673 compared with placebo).
ffects of NAC on expression levels of procollagen genes.
oncordant with histologic data on CVF, expression levels
f Col1a1 and Col1a2 mRNAs were increased by two- to
hree-fold in the placebo group but were normal in the
AC groups (Fig. 3).
igure 3. Expression levels of procollagen genes. Relative expression leve
ol3a1 procollagen genes.ffects of NAC on levels of oxidized nuclear DNA and
tDNA. We detected no significant differences in the
evels of oxidized nuclear DNA and mtDNAs among the
xperiment’s groups (Fig. 4).
ffects of NAC on expression levels of MAPK signaling
olecules. Expression levels of phosphorylated p44/42,
38, and JNK MAPKs were reduced significantly in all
hree NAC groups as compared with placebo or the NTG
roup (Fig. 5), and expression levels of total p44/42, p38,
nd JNK were not changed significantly.
ffects of NAC on the activity of myocardialMMPs. Myo-
ardial MMP-1 (interstitial collagenase) activity was in-
reased by 44  19% in the NAC group as compared with
TG. The difference was of borderline statistical signifi-
ance (p  0.078).
ISCUSSION
n a randomized placebo-controlled study, we showed that
reatment with three different doses of antioxidant NAC
eversed and normalized interstitial fibrosis in a mouse
odel of human HCM mutation without discernible effects
n cardiac function. Treatment with NAC was associated
ith significant reductions in the expression levels of Col1a1
nd Col1a2mRNAs, major collagens in the myocardium. In
rected for the levels in NTG mice, are depicted for Col1a1, Col1a2, and
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N-Acetylcysteine and Fibrosis in HCM February 21, 2006:827–34ddition, myocardial and to a lesser extent plasma levels of
ipid peroxides were also reduced, as were levels of activated
44/42, p38, and JNK proteins. These findings in a trans-
enic mouse model of human HCM illustrate the potential
tility of NAC in treatment of interstitial fibrosis, a major
henotype of human HCM and an important determinant
f arrhythmogenesis and risk of SCD (4,6). Because inter-
titial fibrosis is a common response of the heart to all forms
f stress or injury, the potential beneficial effects of NAC in
eversal of fibrosis may not be restricted to this particular
odel of HCM but could encompass a variety of cardio-
ascular pathologies.
The finding of reversal of established cardiac fibrosis,
lthough novel in a genetic animal model of human HCM
utation, is in accord with the data showing beneficial
ffects of the antioxidants in treatment of fibrosis in other
onditions, including pulmonary, renal, and liver fibrosis
19,20). The observed antifibrotic effects occurred despite
he absence of discernible increase in markers of myocardial
xidative stress in the cTnT-Q92 mice, as detected by levels
f myocardial lipid peroxides and oxidized mtDNA. The
atter finding could reflect the relative insensitivity of the
ethods for detection of a potentially modest and yet
hronic increase in oxidative stress in a genetic animal
odel wherein the stimulus is relatively of low magnitude
igure 4. Oxidized nuclear and mitochondrial DNA levels. (A) mtDNA is
f approximately 8 and 9 kbp, indicating the purity of the isolated mtDNA.
romide stained blot (lower blot) in three mice in each of the experimen
romide stained blot (lower blot) in three mice per experimental group.nd chronic. Therefore, the data do not necessarily exclude cotential involvement of a low level and chronic increase in
xidative stress in the development of interstitial fibrosis in the
TnT-Q92 mice. Alternatively, the finding could also sug-
est that treatment with NAC could impart antifibrotic
ffects in conditions wherein oxidative stress does not play a
ajor or direct role in the pathogenesis of the phenotype.
The molecular mechanism(s) by which NAC imparts the
ntifibrotic effect is yet to be fully determined. Our data
how reduced expression of procollagen genes as a potential
echanism for the antifibrotic effects of NAC in the myocar-
ium. The results also implicate involvement of oxidative
tress-responsive MAPK signaling in mediating the effects.
n addition, myocardial MMP-1 and to a lesser degree
MP-9 activities were increased. However, the changes
ere modest and of borderline statistical significance. Ad-
itional experiments will be required to further delineate the
ole and contribution of MMPs and tissue inhibitors of
etalloproteinases to resolution of interstitial fibrosis in the
TnT-Q92 mice. N-acetylcysteine is a precursor for gluta-
hione, the most abundant intracellular non-protein thiol
nd a major redox molecule with various functions (19).
lutathione scavenges free radicals and other reactive oxy-
en species, reacts with other metabolites as well as with
itric oxide, and participates in the generation of prosta-
landins (19). Oxidative stress and other noxious stimuli
and digested with BamH1 restriction enzyme, which results in two bands
mmuno-slot blot of mtDNA (upper blot) and the corresponding ethidium
oups. (C) Immuno-slot blot (upper blot) of nuclear DNA and ethidiumolated
(B) Iould deplete cellular glutathione, and hence exert adverse
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February 21, 2006:827–34 N-Acetylcysteine and Fibrosis in HCMiological effects, which could be prevented by the admin-
stration of NAC. Accordingly, treatment with NAC has
een shown to abrogate fibrosis induced by transforming
rowth factor-beta-1 (23). In addition, NAC could suppress
xpression of the procollagen genes even in the absence of
ransforming growth factor-beta-1 (23,24). As shown in the
resent study, treatment with NAC inhibited activation of
44/42, p38, and JNK kinases, important mediators of cell
ignaling in response to many forms of stress or injury. In
ddition, treatment with NAC has been shown to prevent
ctivation of redox-sensitive activating protein-1 and nu-
lear factor kappa B transcription factors (19). Thus, the
ntifibrotic effects of NAC could entail multiple interacting
r independent pathways, not necessarily restricted to tran-
criptional regulation of procollagen genes but also post-
ranslational modifications of the expressed proteins.
In the absence of an effective therapy to reverse or
ttenuate interstitial fibrosis in human patients with HCM,
he findings of this study, once extended to human patients
ith HCM, could have considerable clinical implications.
lucidation of the molecular genetic basis of HCM has led
o efforts to identify and establish an effective therapy for the
CM phenotype. We have previously shown the poten-
igure 5. Expression levels of selected signaling kinases. (A) Immunoblots
B, C, and D)Quantitative analysis of the relative levels of phosphorylated
TG group, in the experimental groups. The sum of density of 44 and 42
f 46 and 54 kDa bands were used for quantification of JNK. *p  0.05ially beneficial effects of statins and inhibitors of the fennin-angiotensin-aldosterone system in attenuating an
stablished phenotype in animal models of HCM (15,18). It
s noteworthy that satins as well as the inhibitors of the
ennin-angiotensin-aldosterone system all show antioxidant
ffects, a common theme with the salutary effects of NAC
bserved in the present study. It is intriguing to propose the
ntioxidants as potential therapeutic choices for human
CM. The cTnT-Q92 mice, however, do not show cardiac
ypertrophy, which is often the case in human HCM
aused by mutations in the cTnT protein (8–11). The
henotype in the cTnT-Q92 mice also differs from that in
ressure overload-induced cardiac hypertrophy, wherein
tress-responsive signaling molecules are induced in early
tages of cardiac hypertrophy and in the absence of fibrosis.
he latter is a late phenotype that often occurs after deterio-
ation of cardiac function. Nevertheless, the findings may
ot directly apply to conditions wherein interstitial fibrosis
s accompanied by myocardial hypertrophy, such as most
ases of human HCM. The existing data, however, suggest
hat the antifibrotic effect of NAC is independent of the
nderlying substrate and applicable to a broad range of
athological states (19,20). In addition, the plausibility of
he clinical utility of NAC in treatment of human HCM is
ing expression levels of phosphorylated and total p44/42, p38, and JNK.
2, p38, and JNK, respectively, all normalized to levels in the corresponding
bands were used to quantify levels of p44/42. Similarly, the sum density
irwise comparisons.show
p44/4urther underscored by the known antihypertrophic effects
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onsidered a very safe drug with no known major side
ffects. Thus, HCM, a paradigm of cardiac hypertrophy and
brosis, could prove to be an excellent disease model for the
alutary effects of NAC. Nonetheless, the potential utility of
AC in the treatment of human HCM, although biolog-
cally plausible, must await proof through direct experimen-
ation. It is also noteworthy that there was no significant
orrelation between the extent or resolution of interstitial
brosis and the echocardiographic indexes of ventricular
iastolic function. The finding may reflect the relatively
mall extent of interstitial fibrosis in the cTnT-Q92 mice
6.2% of the myocardium) as well as involvement of additional
xtracellular matrix and cellular proteins, such as titin in the
egulation of diastolic function (27). Finally, the three doses of
AC tested in this study were equally effective and within the
oses shown to exerts biological effects in mice under various
athological states including fibrosis (28–30). Studies will be
eeded to determine the effective antifibrotic and possibly
ntihypertrophic doses of NAC in humans with HCM.
In conclusion, in a randomized placebo-controlled study,
e have shown that treatment with NAC completely
everses established fibrosis in a mouse model of human
CM mutation. The findings could have considerable
mpact for treatment of interstitial fibrosis and possibly
ardiac hypertrophy in humans with HCM. The signifi-
ance of the findings is further enhanced in view of the
bsence of an established effective therapy to reverse inter-
titial fibrosis or hypertrophy in HCM, the most common
ause of SCD in the young (3). Finally, given that interstitial
brosis is a common phenotypic response of the heart to all
orms of stress or injury, the findings could have implications
or treatment of a variety of cardiovascular diseases.
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